Core Viewpoint - Medical device maker Dexcom exceeded Wall Street estimates for third-quarter results, driven by strong demand for its continuous glucose monitoring systems [1] Company Summary - Dexcom reported robust performance in the third quarter, indicating a positive trend in the demand for its products [1] Industry Summary - The continuous glucose monitoring systems market is experiencing significant growth, as evidenced by Dexcom's strong quarterly results [1]

Exhibit 99.1 Dexcom Reports Third Quarter 2025 Financial Results and Updates Full Year 2025 Guidance SAN DIEGO - (BUSINESS WIRE-October 30, 2025) - DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended September 30, 2025. Third Quarter 2025 Financial Highlights: Third Quarter 2025 Strategic Highlights: "During the quarter, we delivered strong revenue results, expanded access to Dexcom G7, and introduced multiple enhancements to Dexcom's digital platform," said Jake ...

Core Viewpoint - A class action lawsuit has been filed against DexCom, Inc. and certain officers for alleged violations of federal securities laws during the Class Period from July 26, 2024, to September 17, 2025, seeking damages for misleading statements regarding the company's products and operations [1][5]. Company Overview - DexCom is a medical device company focused on continuous glucose monitoring (CGM) systems for diabetes management, with key products including the Dexcom G6 and G7 systems launched in 2018 and 2023, respectively [4]. Allegations and Misleading Statements - The lawsuit alleges that DexCom made materially false and misleading statements about the G6 and G7 systems, including unauthorized design changes that compromised their reliability and safety, leading to increased health risks for users [5]. - Specific allegations include overstated claims about the G7's accuracy and functionality, downplaying the severity of issues with the devices, and failing to disclose the risk of regulatory scrutiny and potential legal repercussions [5]. Regulatory Issues - On March 7, 2025, DexCom received a warning letter from the FDA regarding manufacturing and quality management concerns, which led to a significant drop in stock price [6]. - The FDA later published the warning letter, confirming that the G6 and G7 products were "adulterated" due to modifications made without prior approval, resulting in larger inaccuracies and increased risks for users [7]. Market Reactions - Following the FDA's warning and subsequent reports of issues with the G7, DexCom's stock experienced notable declines, including a drop of $7.12 per share (9.15%) on March 10, 2025, and further declines after Oppenheimer downgraded the stock rating due to concerns about the G7's performance [6][8][9]. - A report by Hunterbrook highlighted severe health risks associated with the G7, linking inaccuracies to hospitalizations and fatalities, which further impacted DexCom's stock price, resulting in a drop of $8.99 per share (11.76%) [10][11].

Core Viewpoint - DexCom Inc. is identified as a promising growth stock in the NASDAQ for the next five years, despite a recent price target reduction by Truist analyst Richard Newitter from $102 to $94 while maintaining a Buy rating [1][2]. Group 1: Company Overview - DexCom Inc. specializes in designing, developing, and commercializing continuous glucose monitoring (CGM) systems both in the US and internationally [3]. Group 2: Market Outlook - Truist anticipates healthy revenue and earnings for Q3 2025 across the MedTech sector, although it warns of potential stock volatility [1]. - Stifel has resumed coverage on several MedTech companies, citing an optimistic outlook for sector growth driven by the adoption of CGMs and insulin pumps, particularly highlighting long-term growth opportunities in the CGM market for Type 2 Basal-only and Type 2 Non-insulin patient segments [2].

Core Viewpoint - DexCom's shares have underperformed the broader market in 2025, down 11% year to date, primarily due to legal and regulatory challenges impacting its performance [1][8] Financial Performance - Despite the stock's decline, DexCom's financial results have been strong, with expectations for continued growth in the upcoming quarterly update on October 30 [2][6] - The company's guidance for fiscal 2025 indicates a year-over-year revenue growth of approximately 14% to 15%, which is critical for maintaining investor confidence [6] Product and Market Position - DexCom is a leading player in the continuous glucose monitoring (CGM) market, with its latest device, the G7, launched in the U.S. in 2023 [3][7] - Some patients have reported issues with inaccurate readings from the G7 device, leading to class action lawsuits, although the majority of customers are still using older G6 devices [4][6] Regulatory Challenges - The company received a warning letter from the U.S. Food and Drug Administration regarding manufacturing issues, which negatively impacted its stock price [5][8] - Monitoring how DexCom addresses these regulatory challenges will be crucial in the upcoming quarterly update [6] Competitive Landscape - DexCom faces competition from Abbott Laboratories, which has also experienced quality control issues with its FreeStyle Libre device, yet remains a significant growth driver for Abbott [7]

NEW YORK, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against DexCom, Inc. (“DexCom” or “the Company”) (NASDAQ: DXCM) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired DexCom securitie ...

Core Insights - DexCom (DXCM) is expected to report quarterly earnings of $0.57 per share, reflecting a 26.7% increase year-over-year, with revenues projected at $1.18 billion, an 18.4% increase compared to the previous year [1]. Earnings Estimates - The consensus EPS estimate has been revised downward by 0.8% in the last 30 days, indicating a reassessment by analysts [2]. - Revisions to earnings projections are crucial for predicting investor behavior and are linked to short-term stock price performance [3]. Revenue Projections - Analysts estimate 'Revenue- Hardware' to be $39.65 million, showing a year-over-year decline of 6.5% [4]. - 'Revenue- Sensor and other' is projected at $1.14 billion, indicating a 19.6% increase from the year-ago quarter [5]. - 'Revenue- United States' is expected to reach $843.25 million, reflecting a 20.1% year-over-year increase [5]. - 'Revenue- International' is forecasted at $332.15 million, suggesting a 13.6% increase compared to the previous year [5]. Stock Performance - Over the past month, DexCom shares have returned 2.9%, while the Zacks S&P 500 composite has increased by 3.8% [6]. - Currently, DexCom holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the overall market in the near future [6].

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit against DexCom, Inc. on behalf of shareholders who purchased securities between July 26, 2024, and September 17, 2025, alleging that the company misled investors regarding its business operations [1][2]. Allegations - The lawsuit claims that DexCom made unauthorized material design changes to its G6 and G7 continuous glucose monitoring systems, which rendered them less reliable and posed health risks to users [3]. - It is alleged that the enhancements to the G7 device were overstated, and the company downplayed the severity of issues related to the G7 devices [3]. - The lawsuit suggests that these actions increased DexCom's risk of regulatory scrutiny and potential legal, reputational, and financial harm [3]. - Investors reportedly suffered damages when the true details about the devices were revealed [3]. Next Steps for Shareholders - Shareholders wishing to serve as lead plaintiffs must file motions with the court by December 29, 2025 [4]. - Participation in the case is not required to be eligible for recovery, allowing shareholders to remain absent class members if they choose [4]. About Rosen Law Firm - Rosen Law Firm is recognized for its commitment to shareholder rights litigation and has recovered over $1 billion for shareholders since its inception [6].

Core Viewpoint - DexCom, Inc. is facing a class action lawsuit alleging that the company made materially false and misleading statements regarding its G6 and G7 devices, which may have health risks for users [3]. Group 1: Lawsuit Details - The class action is on behalf of investors who purchased DexCom securities between July 26, 2024, and September 17, 2025, with a deadline of December 26, 2025, for filing a lead plaintiff motion [1]. - Allegations include unauthorized design changes to the G6 and G7 devices that compromised their reliability and safety, posing health risks to users [3]. - The lawsuit claims that DexCom overstated the enhancements and reliability of the G7 devices while downplaying the severity of the issues related to the devices [3]. Group 2: Legal Representation - The Portnoy Law Firm is representing investors in this case and offers complimentary case evaluations to discuss options for recovering losses [2][4]. - The founding partner of the Portnoy Law Firm has a track record of recovering over $5.5 billion for investors affected by corporate wrongdoing [4].

Core Insights - DexCom Inc is under scrutiny following reports of three deaths linked to its G7 continuous glucose monitor, raising safety concerns about the device [1][4]. - An investigation by Hunterbrook criticized DexCom for failing to ensure the accuracy and reliability of the G7 device, with reports of severe complications among patients [2]. - Class action lawsuits have been filed against DexCom, alleging misleading information regarding the accuracy of its monitoring system [3]. Regulatory and Legal Issues - The FDA's MAUDE database has recorded at least 13 deaths associated with the G7 since its launch in 2023, highlighting ongoing safety issues [5]. - A warning letter was issued to DexCom by the FDA in March 2025, citing potential sensor malfunctions and communication errors [6]. - Legal actions include class action lawsuits and a separate securities lawsuit filed against the company [3]. Market Performance - DexCom's stock has seen a decline, with shares down 2.87% to $68.59 at the time of publication [6].